🔗 Share this article

While America undertakes sweeping changes to its vaccine recommendations, one figure has emerged unexpectedly: Høeg, a Danish American physician and public health researcher who first made her name by casting doubt on coronavirus shots during the pandemic and has concentrated on possible deaths after Covid immunization in her brief tenure at the Food and Drug Administration.

Proposed Shifts to Childhood Immunization Program

Public health authorities planned to reveal sweeping revisions to the childhood immunization program earlier this month, bringing the US with the Danish national calendar, according to reports – a substantial departure that would place the US out of alignment with much of the international standard with no evidence for improved outcomes. The announcement has been pushed back until the coming year.

Rather than the top vaccines chief, Høeg is listed to present at the gathering. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth individual to head the division this year.

A New Direction at the Agency

This interim role may indicate a tighter collaboration between the drug and biologics centers as Høeg and Prasad consolidate power at the FDA – and it suggests a increased emphasis upon rolling back previously authorized vaccines at the FDA.

Dr. Høeg has often pushed for discontinuing specific childhood vaccine recommendations in the US in order to be more in line with Denmark, a nation with comprehensive healthcare and a population about the population of Wisconsin’s.

To date public appearances, she has continued to focus on immunizations – traditionally the purview of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Questions Over Qualifications

Høeg has no obvious background in drug development, oversight or administrative roles, which has been typical for former heads of the CBER. She has been employed at the FDA as a top consultant to the commissioner and CBER since earlier this year.

“She appears not to have the requisite experience” for overseeing the drug-regulation department, remarked Jonathan Howard. “She’s never run a clinical trial. She is not versed in running a sizeable institution. She lacks background in industry regulation.”

Former commissioners of the center would “understand regulatory frameworks and the research of drug development”, noted Dr. Janet Woodcock. “Objectively, she doesn’t have the type of experience that former directors who headed CBER have had.”

The drug center has an vast workload at the agency, she pointed out.

“The public just zeroes in on the innovative therapies, but the generic drug division authorizes numerous off-brand pharmaceuticals. There is also a biologic copycat branch, OTC medication office and so forth, and all of those need to be looked after,” she explained. “The responsibility you overlook, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a significant administrative element to the role, which oversees in excess of 5,000 staff members. “It’s a enormous administrative position, if you perform it correctly,” the former official added.

Response and Contentious Policies

In response to concerns about Dr. Høeg's credentials and whether this selection signifies greater collaboration among FDA leaders on immunizations, a press secretary said that the “concerns rely on inaccurate assumptions”.

“Her resume is consistent with the functions of her job,” the official stated, pointing to the period Høeg spent advising the agency head on “drug safety and oversight research, including computational safety modeling and immunization monitoring”.

As the temporary head, Høeg assumes responsibility for the agency head's new expedited review system, a disputed one-day drug-approval program that reportedly troubled her former heads. “How are these therapies being chosen for this expedited pathway? Who takes the decisions?” Dr. Howard questioned. “There’s a lot of confidentiality occurring at the agency right now.”

Broadly speaking, he remarked, “the Food and Drug Administration looks to be trending towards less stringent oversight of pharmaceuticals, aside from vaccines.”

Public History on Vaccines

Concerning immunizations, Dr. Høeg has a clearer, if problematic, history, critics have noted. She published a research paper using unconfirmed volunteer-provided data to estimate the rate of myocarditis following COVID-19 immunization. She counseled the state of Florida top health official Dr. Joseph Ladapo, who was said to have changed statistics to indicate COVID-19 vaccinations are more dangerous than they are.

Part of her “wish list” for the incoming federal leadership included revising guidelines for new vaccines and halting “unnecessary” vaccines, she said after the election on a online show. At the agency, Dr. Høeg has reportedly proposed barring teenage boys from receiving COVID-19 vaccines.

“She is an complete dogmatist who commences with her beliefs and tailors the evidence to retrofit the data in a highly disingenuous, untruthful way,” Dr. Howard said.

Taking Control and a “Revenge Tour”

Høeg joined fellow contrarians, {like|